Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.


TSX:EDT - Post by User

Bullboard Posts
Comment by imatryinon Mar 20, 2019 2:21pm
159 Views
Post# 29512302

RE:RE:email to Doc Walker re US distribution

RE:RE:email to Doc Walker re US distributionPleased to say I got a response, and a quick one at that!  I should have asked if there were plans to list in the US.

"Unfortunately none of the wire services will post a press release unless we are listed in the US.
 
Please send me your full name and email address and I will make sure you are sent one form our Canadian IR group
 
Thank you for your continuing support.
 
Paul"

mercedesman wrote:
imatryin wrote:
Not holding my breath on a response.

Hi Dr. Walker,
 
I am a long-holding owner of Spectral stock and would like to understand why the company does not distribute its press releases in the US.  I'm sure I don't have to state the obvious as to why it is important, and clearly it must be a calculated choice.  As a shareholder I am confident in the value that Spectral holds or I wouldn't stay in it, but it is getting increasingly frustrating to see the lack of marketing efforts, especially when lesser stage competitive companies are enjoying many multiples the shareholder value.
 
Respectfully,
XX


Good email XX (lol). I wish you good luck in getting a response. My understanding is that moving up a few tiers on the OTC market would cost under $ 100k per year (which also comes with full news dissemination in the US). Of course full Nasdaq listings have other requirements, including market cap, more onerous SEC and Audit requirements etc. and a bigger bean-counting staff (probably costs closer to $500k to $ 1m annually). However you could much more easily raise capital (at say $ 1 USD, for example - pre reverse split), with far less dilution. So what's an extra million $ in costs and personnel ? 20M shares in the US raises $ 27M CAD$ at $ 1 USD issuance price. It's a bit of a chicken/egg problem, but very doable, and in fact done all the time. MM


Bullboard Posts